医学信息
醫學信息
의학신식
MEDICAL INFORMATION
2014年
5期
24-24
,共1页
冠心病%骨桥蛋白%血管紧张素转换酶抑制剂%醛固酮受体拮抗剂%冠状动脉介入治疗
冠心病%骨橋蛋白%血管緊張素轉換酶抑製劑%醛固酮受體拮抗劑%冠狀動脈介入治療
관심병%골교단백%혈관긴장소전환매억제제%철고동수체길항제%관상동맥개입치료
Coronary artery disease%Osteopontin%Angiotensin converting enzyme inhibitor%Percutaneous coronary intervention%Aldosterone receptor antagonist
目的：观察血管紧张素转换酶抑制剂（ACEI）和/或醛固酮受体拮抗剂对冠心病患者介入治疗（PCI）后血浆骨桥蛋白（OPN）的影响。方法因冠心病接受 PCI治疗的100例患者随机分为常规治疗组、福新普利组（10 mg/d），依普利酮组（10 mg/d），联合用药组（各5 mg/d）。治疗1次/d，持续14d。因冠心病行冠脉造影但无需PCI术患者25例作为对照组。分别于术前、术后3d和术后14d测定血浆OPN浓度。结果各组间介入治疗前血浆OPN表达无显著差异，术后呈时间依赖性升高。给予ACEI及醛固酮受体拮抗剂干预后，术后14d OPN表达水平显著降低，以联合用药组下降最为明显。结论 PCI术后血浆OPN水平升高，而ACEI与醛固酮受体拮抗剂均能降低OPN表达，且联合用药最为明显。 ACEI与醛固酮受体拮抗剂联合应用可降低血浆 OPN表达，抑制血管内皮损伤，防治PCI术后再狭窄。
目的：觀察血管緊張素轉換酶抑製劑（ACEI）和/或醛固酮受體拮抗劑對冠心病患者介入治療（PCI）後血漿骨橋蛋白（OPN）的影響。方法因冠心病接受 PCI治療的100例患者隨機分為常規治療組、福新普利組（10 mg/d），依普利酮組（10 mg/d），聯閤用藥組（各5 mg/d）。治療1次/d，持續14d。因冠心病行冠脈造影但無需PCI術患者25例作為對照組。分彆于術前、術後3d和術後14d測定血漿OPN濃度。結果各組間介入治療前血漿OPN錶達無顯著差異，術後呈時間依賴性升高。給予ACEI及醛固酮受體拮抗劑榦預後，術後14d OPN錶達水平顯著降低，以聯閤用藥組下降最為明顯。結論 PCI術後血漿OPN水平升高，而ACEI與醛固酮受體拮抗劑均能降低OPN錶達，且聯閤用藥最為明顯。 ACEI與醛固酮受體拮抗劑聯閤應用可降低血漿 OPN錶達，抑製血管內皮損傷，防治PCI術後再狹窄。
목적：관찰혈관긴장소전환매억제제（ACEI）화/혹철고동수체길항제대관심병환자개입치료（PCI）후혈장골교단백（OPN）적영향。방법인관심병접수 PCI치료적100례환자수궤분위상규치료조、복신보리조（10 mg/d），의보리동조（10 mg/d），연합용약조（각5 mg/d）。치료1차/d，지속14d。인관심병행관맥조영단무수PCI술환자25례작위대조조。분별우술전、술후3d화술후14d측정혈장OPN농도。결과각조간개입치료전혈장OPN표체무현저차이，술후정시간의뢰성승고。급여ACEI급철고동수체길항제간예후，술후14d OPN표체수평현저강저，이연합용약조하강최위명현。결론 PCI술후혈장OPN수평승고，이ACEI여철고동수체길항제균능강저OPN표체，차연합용약최위명현。 ACEI여철고동수체길항제연합응용가강저혈장 OPN표체，억제혈관내피손상，방치PCI술후재협착。
Objective: This study was to investigate the ef ect of fosinopril and eplerenone on the plasma level of osteopontin (OPN) in coronary artery disease (CAD) patients receiving percutaneous coronary intervention (PCI). Method: A total of 100 patients with coronary artery disease receiving PCI were randomly divided into 4 groups: PCI group, fosinopril (F; 10 mg/d) group, eplerenone (E; 10 mg/d) group and F+E group (5 mg/d for each) (n=25 per group). Another 25 CAD patients receiving coronary angiography alone were also recruited as controls. The plasma OPN levels were measured preoperatively and 3 and 14 days postoperatively. Results: There was no significant dif erence in preoperative plasma OPN level among al groups. After PCI, the plasma OPN increased with a time-dependent manner. After treatment with fosinopril and/or eplerenone, the postoperative plasma OPN level decreased markedly at 14 days, and the highest reduction was found in the F+E group. Conclusion: PCI may lead to an increase in plasma OPN, and ACEI and/or aldosterone receptor antagonist can decrease the PCI-induced OPN increase. ACEI and/or aldosterone receptor antagonist can exert synergistic ef ect to prevent postoperative restenosis in CAD patients receiving PCI.
